Skip to main content
. 2019 Jul 26;11(6):1053–1063. doi: 10.1080/19420862.2019.1630218

Figure 3.

Figure 3.

MS/MS spectra of pronase-treated O-glycopeptides of atacicept. (a) Stepping-energy CID spectra of the O-glycopeptide 86SDKT89 covering glycosylation site Ser86 with a monosialylated core 1-type glycan. (b) Stepping-energy CID spectra of the O-glycopeptide 91TCPPCPAPE99 covering the glycosylation site Thr91 with a monosialylated core 1-type glycan. (c + d) ETD spectra of the O-glycopeptide 86SDKT89 covering glycosylation site Ser86 carrying a monosialylated core 1-type glycan from two different production batches. Compounds with the same mass and retention time from two different production batches were compared featuring the same fragmentation pattern and thus, could be identified as the same glycopeptides.